| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.0074 | 0.9 |